Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TJ7S
|
|||
| Former ID |
DIB007040
|
|||
| Drug Name |
PDC-41
|
|||
| Synonyms |
THG-113; THG-113.31; PDC-31 (iv, premature labor); PGF2 alpha antagonist (primary dysmenorrhea/topical), PDC Biotech; Prostaglandin F2 alpha antagonist (primary dysmenorrhea/topical), PDC Biotech; PDC-31 (iv, premature labor), PDC; PGF2 alpha antagonist (injectable, premature labor/dysmenorrhea), PDC Biotech; Prostaglandin F2 alpha antagonist (injectable, premature labor/dysmenorrhea), PDC Biotech
Click to Show/Hide
|
|||
| Indication | Dysmenorrhea [ICD-11: GA34.3; ICD-9: 625.3] | Phase 1 | [1] | |
| Company |
Theratechnologies Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin F2-alpha receptor (PTGFR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01250587) Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea. U.S. National Institutes of Health. | |||
| REF 2 | THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.